Figure 1
Moving beyond neuroendocrine blockade to treat heart failure. Neuroendocrine blockade remains the cornerstone of HF therapy, while new approaches targeting metabolic remodelling and inflammation are emerging as promising therapeutic options. ACE, angiotensin-converting enzyme; AT1, angiotensin receptor type 1; SGLT2, sodium/glucose transporter 2.

Moving beyond neuroendocrine blockade to treat heart failure. Neuroendocrine blockade remains the cornerstone of HF therapy, while new approaches targeting metabolic remodelling and inflammation are emerging as promising therapeutic options. ACE, angiotensin-converting enzyme; AT1, angiotensin receptor type 1; SGLT2, sodium/glucose transporter 2.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close